Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -13.78% is 72% above its 5-year average of -49.65%, near the high end of its 5-year range (-369.45%–57.03%).
60.24% above its 12-month average of -34.66%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -5.03%.
NET PROFIT MARGIN
-13.78%
NET PROFIT MARGIN AVG TTM
-34.66%
NET PROFIT MARGIN AVG 3Y
-49.06%
NET PROFIT MARGIN AVG 5Y
-49.65%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+60.24%
CURRENT VS 3Y AVG
+71.91%
CURRENT VS 5Y AVG
+72.25%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-3837.14%
vs the sector median at left
Biofrontera Inc.
Market Cap
$11.93M
Net Profit Margin
-13.78%
TTM Avg
-34.66%
3Y Avg
-49.06%
5Y Avg
-49.65%
Market Cap
$12.06M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$11.77M
Net Profit Margin
-6.88%
TTM Avg
-8.42%
3Y Avg
-15.06%
5Y Avg
-13.62%
Market Cap
$12.17M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$11.55M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$12.44M
Net Profit Margin
-48.94%
TTM Avg
-40.16%
3Y Avg
-67.25%
5Y Avg
-58.35%
Market Cap
$12.48M
Net Profit Margin
-804.37%
TTM Avg
-21365.78%
3Y Avg
-11028.80%
5Y Avg
-7352.54%
Market Cap
$11.36M
Net Profit Margin
-666037.76%
TTM Avg
-148948.78%
3Y Avg
-148948.78%
5Y Avg
-148948.78%
Market Cap
$12.58M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biofrontera Inc. (BFRI) | $11.93M | -13.78% | -34.66% | -49.06% | -49.65% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.06M | 0.00% | 0.00% | 0.00% | 0.00% |
| IRIDEX Corporation (IRIX)vs › | $11.77M | -6.88% | -8.42% | -15.06% | -13.62% |
| Lantern Pharma Inc. (LTRN)vs › | $12.17M | 0.00% | 0.00% | 0.00% | 0.00% |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.55M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cytosorbents Corporation (CTSO)vs › | $12.44M | -48.94% | -40.16% | -67.25% | -58.35% |
| Dare Bioscience, Inc. (DARE)vs › | $12.48M | -804.37% | -21365.78% | -11028.80% | -7352.54% |
| Caring Brands, Inc. (CABR)vs › | $11.36M | -666037.76% | -148948.78% | -148948.78% | -148948.78% |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.58M | 0.00% | 0.00% | 0.00% | 0.00% |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.12M | -2702.64% | -8035.59% | 1817.42% | 219.40% |
Operating Margin
-21.9%
Net Profit Margin
-13.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -5.03% |
| 2026-03-31 | -47.12% |
| 2025-12-31 | 32.98% |
| 2025-09-30 | -95.15% |
| 2025-06-30 | -58.96% |
| 2025-03-31 | -48.94% |
| 2024-12-31 | -11.12% |
| 2024-09-30 | -62.91% |
| 2024-06-30 | -3.28% |
| 2024-03-31 | -132.10% |
| 2023-12-31 | 33.28% |
| 2023-09-30 | -71.29% |
| 2023-06-30 | -168.21% |
| 2023-03-31 | -85.63% |
| 2022-12-31 | -27.45% |
| 2022-09-30 | -59.37% |
| 2022-06-30 | -19.07% |
| 2022-03-31 | 57.03% |
| 2021-12-31 | -158.21% |
| 2021-09-30 | -369.45% |
| 2021-06-30 | -62.53% |
| 2021-03-31 | -74.49% |
| 2020-12-31 | -2.17% |
| 2020-09-30 | -91.79% |
| 2020-06-30 | -154.54% |
| 2020-03-31 | -88.77% |
